Clinical Trial Update: SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining SGI-110 with donor lymphocyte infusions after allogeneic stem cell transplantation for myelodysplastic syndromes and acu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• SGI-110 (guadecitabine)
• donor lymphocyte infusions (DLI)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN